Compare Berkshire Hathaway Inc Class B (BRK.B) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs ResMed Inc. — how do they compare? Berkshire Hathaway Inc Class B trades at $491.66, while ResMed Inc. trades at $193 (market cap $28.00B). The key difference: ResMed Inc. pays a 1.24% dividend while Berkshire Hathaway Inc Class B pays none, and Berkshire Hathaway Inc Class B is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| BRK.B | RMD | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $513.70 | $293.73 |
52-Week Low | $459.10 | $182.82 |
Market Cap | — | $28.00B |
Enterprise Value | — | $27.18B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Berkshire Hathaway Class B shares (BRK.B) trade at $496.79, up 0.63% on the day, with a bullish technical signal from moving averages. Analyst consensus is positive with 57% buy ratings. The stock's current price is near the pivot point of $497, with immediate resistance at $500 and support at $494.
The outlook remains favorable given strong institutional confidence and the company's diversified holdings, though risks include market volatility and economic cycles. Upside potential exists if the stock breaks above $500 resistance, supported by bullish momentum indicators.
ResMed (RMD) trades at $198.50, down 2.63% on the day, with technical indicators showing a bearish trend near support at $197. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $2.86 versus $2.80 expected, and robust profitability with a 27.44% net margin. Recent strategic moves include the sale of its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets.
The outlook remains positive given analyst consensus targets near $249.57, representing significant upside, though near-term technical weakness and competitive pressures in digital health pose risks. Revenue growth is projected to reach $5.5 billion in 2026, supporting a solid investment case for long-term holders despite current bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
